MTOR and autoimmune thrombocytopenic purpura: In previous studies, the mTOR inhibitor rapamycin was reported to reduce drug toxicity and reverse treatment resistance in combination with ICIs (Beeram et al., 2007; Esfahani et al., 2019), showing therapeutic potential against ICIs-induced ITP.